Asset Sale (Details Narrative) - Titan Pharmaceuticals Inc [Member] |
1 Months Ended |
|---|---|
|
Aug. 31, 2023
USD ($)
| |
| Asset purchase price | $ 2,000,000.0 |
| Asset transfered | 500,000 |
| Cash note | 500,000 |
| Escrow deposit | 1,000,000 |
| Payment for extension | $ 5,000 |
| X | ||||||||||
- Definition Asset acquisition price of acquisition. No definition available.
|
| X | ||||||||||
- Definition Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Payments of cash to employees, including wages and salaries, during the current period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|